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ARTICLE
Oral Curcumin Mitigates the Clinical and Neuropathologic
Phenotype of the Trembler-J Mouse: A Potential Therapy
for Inherited Neuropathy
Mehrdad Khajavi, Kensuke Shiga, Wojciech Wiszniewski, Feng He, Chad A. Shaw, Jiong Yan,
Theodore G. Wensel, G. Jackson Snipes, and James R. Lupski
Mutations in myelin genes cause inherited peripheral neuropathies that range in severity from adult-onset Charcot-
Marie-Tooth disease type 1 to childhood-onset Dejerine-Sottas neuropathy and congenital hypomyelinating neuropathy.
Many myelin gene mutants that cause severe disease, such as those in the myelin protein zero gene (MPZ) and the
peripheral myelin protein 22 gene (PMP22), appear to make aberrant proteins that accumulate primarily within the
endoplasmic reticulum (ER), resulting in Schwann cell death by apoptosis and, subsequently, peripheral neuropathy.We
previously showed that curcumin supplementation could abrogate ER retention and aggregation-induced apoptosis as-
sociated with neuropathy-causing MPZ mutants. We now show reduced apoptosis after curcumin treatment of cells in
tissue culture that express PMP22 mutants. Furthermore, we demonstrate that oral administration of curcumin partially
mitigates the severe neuropathy phenotype of the Trembler-J mouse model in a dose-dependent manner. Administration
of curcumin signiﬁcantly decreases the percentage of apoptotic Schwann cells and results in increased number and size
of myelinated axons in sciatic nerves, leading to improved motor performance. Our ﬁndings indicate that curcumin
treatment is sufﬁcient to relieve the toxic effect of mutant aggregation-induced apoptosis and improves the neuropath-
ologic phenotype in an animal model of human neuropathy, suggesting a potential therapeutic role in selected forms
of inherited peripheral neuropathies.
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Human inherited peripheral neuropathies are often a
manifestation of peripheral myelin dysfunction and have
long been proposed to result from abnormalities in
Schwann cells and their myelin sheath and perturbed
axon-glia interactions. The hereditary motor and sensory
neuropathies are the largest class of hereditary neuropa-
thies and include Charcot-Marie-Tooth disease (CMT)
types 1 and 2 (CMT1 [MIM 118200] and CMT2 [MIM
600882]), hereditary neuropathy with liability to pressure
palsies (HNPP [MIM 162500]), Dejerine-Sottas neuropathy
(DSN [MIM 145900]), and congenital hypomyelinating
neuropathy (CHN [MIM 605253]). CMT is the most com-
mon inherited disorder of the peripheral nervous system,
with an estimated frequency of 1 in 2,500 individuals.1
Patients with CMT usually manifest symptoms in the 1st
or 2nd decade, with slowly progressive, symmetrical,
length-dependent neuropathy leading to weakness of the
distal muscles of the legs and feet, followed in most cases
by involvement of the hands.2–4 CMT1, the demyelinating
form, is characterized by a slowing of the motor-nerve
conduction velocities (usually to !38 m/s).2
Themolecular cause of CMT1 in themajority of patients
is a duplication of a 1.4-Mb region on the short arm of
chromosome 17, to which the dosage-sensitive peripheral
myelin protein 22 gene (PMP22) maps.5–7 The reciprocal
deletion of the same region is associated with a milder
disease, HNPP.8–10 PMP22, a 22-kDa glycoprotein with four
putative transmembrane domains, comprises 2%–5% of
peripheral nervous system myelin11 and is found uni-
formly in compact regions of myelin.12,13 AlthoughPMP22
is widely expressed, by far the largest amount of PMP22
is produced by myelinating Schwann cells. It is clear from
both human studies7 and animal models14 that alteration
in PMP22 gene dosage and expression has profound effects
on the development and maintenance of peripheral
nerves.2,10 Consequently, the regulation of PMP22 gene
expression has been the focus of therapeutic strategies
for CMT1A.15–16 Onapristone, a progesterone antagonist,
slows the disease progression by reducing the level of over-
expression of PMP22 in a CMT1A transgenic rat model,
consequently improving the CMT phenotype.15 Ascorbic
acid treatment also signiﬁcantly improves locomotor per-
formance of CMT1A transgenic mouse models, possibly
by blunting stimulation of cyclic adenosine monophos-
phate and thereby reducing the expression of PMP22 to
below the threshold level, enough to partially ameliorate
the neuropathy.16 These therapeutic approaches show
promise in animal studies, but they are not feasible for
other genetic causes of CMT because suchmolecular strat-
egies apply only to PMP22 overexpression.
PMP22 point mutations can also cause demyelinating
neuropathies, such as CMT1, DSN, CHN, and HNPP (In-
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herited Peripheral Neuropathies Mutation Database). The
spontaneously occurring mouse models for CMT1, Trem-
bler-J (Tr-J) (with mutation L16P) and Trembler (Tr) (with
mutation G150D) result from dominantly transmitted
PMP22 missense mutations.17,18 More recently, additional
mouse Pmp22 mutations that phenocopy more-severe hu-
man peripheral neuropathies, such as DSN, were isolated
in a large-scale ethylnitrosourea mutagenesis screen.19 Of
note, severely affected patients with CMT1 with identical
mutations and nerve biopsy results showing alterations
analogous to those detected in heterozygous Tr-J and Tr
mice have been described.14,20,21 The pathomechanism
for how these mutations affect myelination remains
unknown; however, recent studies have shown that post-
translational events, such as protein processing, trafﬁck-
ing, and accumulation in different intracellular compart-
ments, are critical for myelination of Schwann cells.22–25
Recent experiments in diverse disease animal models
suggest that curcumin enables misfolded proteins to tra-
verse from the endoplasmic reticulum (ER) to the plasma
membrane,26–29 concurrently reducing the cytotoxicity of
the mutant protein. Such observations have led us to ex-
plore the effects of curcumin in wild-type PMP22, Tr-J, and
Tr mutants, using both cell-based and whole-animal as-
says. We studied the effects of curcumin on the wild-type
and aggregation-induced apoptosis associated with dis-
ease-causing mutant PMP22 in transiently transfected
HeLa cells. As we had observed previously for disease-as-
sociated MPZ alleles,29 the Tr-J and Tr mutant proteins
appear to be partially released from the ER after curcumin
treatment; this is also associated with reduced apoptosis
of cells in tissue culture. To evaluate the effects of cur-
cumin in vivo, curcumin was administered orally to Tr-J
mice. We observed considerable improvement of the neu-
ropathy, including both the motor performance and the
histopathology of the treated Tr-J mice, suggesting a po-
tential therapeutic use for curcumin in severe forms of
inherited peripheral neuropathy.
Material and Methods
Recombinant Constructs
Full-length human PMP22 cDNA was subcloned into expression
vector pcDNA3.1 (Invitrogen). Mutations were generated in each
construct by use of the QuikChange site-directed mutagenesis kit
(Stratagene). Primer sets were designed to create the following
mutations: 47TrC (L16P; Tr-J) and 449GrC (G150D; Tr). Clones
were veriﬁed by direct double-stranded DNA sequencing with use
of the DyePrimer chemistry and ABI 377 sequencer (Applied
Biosystems).
Tissue Culture, Transfection, and Immunostaining
HeLa cells were grown on a 6-well chamber ﬂask and 4-well slides
in Dulbecco’s modiﬁed Eagle medium (BioWhittaker), supple-
mented with 10% fetal bovine serum, and were transfected with
use of Lipofectamine 2000 (Invitrogen) in accordance with the
supplier’s instructions. Cells were incubated for 24 h at 37C in
a humidiﬁed incubator containing 10% CO2. Cells were ﬁxed
with 2% paraformaldehyde in PBS at room temperature for 10
min. The ﬁxed cells were then washed and permeabilized with
0.1% Triton-X 100 in PBS on ice for 2 min. The cells were rinsed
twice with PBS and were blocked with 5% normal goat serum in
PBS for 1 h at 37C. They were incubated with primary antibodies
diluted in PBS with 1% normal goat serum at appropriate con-
centrations for 1 h at 37C. The primary antibodies used in this
study included the rabbit polyclonal antibody against PMP22pro-
tein (1:1,000 [Novus Biologicals]) and the mouse monoclonal
protein disulﬁde isomerase (PDI) (1:2,000 [Afﬁnity Bioreagents]).
This incubation was followed by two washes in PBS and incu-
bation with Alexa Fluor goat anti-rabbit antibody (1:1,000 [In-
vitrogen Molecular Probe]) for 1 h at 37C. For visualization of
the nuclei, SlowFade Antifade Kit with 4′6-diamino-2-phenylin-
dole (DAPI) (Invitrogen Molecular Probe) was used in accordance
with the manufacturer’s instructions. Fluorescently labeled cells
were visualized by standard ﬂuorescent microscopy.
Apoptosis Assay and Flow-Cytometric Analysis
Terminal deoxynucleotidyl transferase biotin-dUTP nick end la-
beling (TUNEL) staining was performed with use of an in situ
cell-death detection kit, Fluorescein (Roche Applied Science).
Cells were grown in four chamber slides and were ﬁxed with 4%
paraformaldehyde in PBS at room temperature for 10 min. Cells
were then washed and permeabilized with 0.1% Triton-X 100 in
PBS on ice for 2 min. TUNEL staining was performed in accor-
dance with the conditions recommended by the supplier (for 1
h at 37C). The average numbers of TUNEL-positive and DAPI-
positive cells were calculated in 10 different sections, and the SD
of the ratio was determined for each slide. Student’s t tests com-
paring wild-type PMP22 and its mutants were performed. Sta-
tistical signiﬁcance was deﬁned by . For ﬂuorescence-P ! .05
activated cell sorting (FACS) analysis, cells were transiently
transfected for 24 h and then were harvested. Staining with an-
nexin V, ﬂuorescein isothiocyanate (FITC), and propidium iodide
(BD Biosciences Pharmingen) was performed by the incubation
of cells ( cells/ml) in the dark for 25 min at room tem-61# 10
perature in a binding buffer (10 mM HEPES, 140 mM NaCl, and
2.5 mM CaCl2, at pH 7.4) containing a saturating concentration
of annexin V, FITC, and propidium iodide. After incubation, the
cells were washed, pelleted, and analyzed in an FACScan analyzer
(Becton Dickinson). For in vivo TUNEL analysis, sciatic nerves
were removed from mice immediately after death and were cut
and ﬁxed in 2.5% gluteraldehyde and 0.5% paraformaldehyde in
0.1 M phosphate buffer for at least 2 h. Nerve segments were then
dehydrated in a graded series of ethanol and were embedded in
parafﬁn. Longitudinal sections, 7 mm thick, were mounted on
slides and then were dewaxed and rehydrated. In vivo TUNEL
analysis was performed using ApopTag Peroxidase In Situ Apo-
ptosis Detection kit (Chemicon International) in accordancewith
the supplier’s instructions.
Genotyping
Genomic DNA was isolated from the tails of newborn mouse
pups, and Tr-J mice (C57BL/6J) were genotyped as described
elsewhere.22
Curcumin Treatment
Curcumin was purchased from Sigma (catalog number C7727).
For cell culture treatment, curcumin stock was dissolved in di-
440 The American Journal of Human Genetics Volume 81 September 2007 www.ajhg.org
Figure 1. Release of ER-retained Tr-J and Tr mutants with cur-
cumin treatment. A, Subcellular localization of wild-type (Wt)
PMP22, Tr-J, and Tr in transiently transfected HeLa cells. Tr-J and
Tr are extensively retained in the ER, as evidenced by colocalization
with PDI (arrows in f and i). B, Curcumin treatment of HeLa cells
rescues Tr-J and Tr mutants (green) retained in the ER (PDI markers
[red]), as revealed by increased cytoplasmic staining. Cells treated
with 40 mM curcumin showed reduced ER retention (arrows in f
and i). Scale bars p 25 mm.
methylsulfoxide in accordance with the conditions recom-
mended by the supplier. Cells were pretreated with curcumin (40
mM) for 3 h before transfection. For mice treatment, curcumin
stock was dissolved in alimentum for 1 h before treatment. Each
animal was treated with a daily dose of 0, 50, or 100 mg of cur-
cumin per kg of body weight by gastric lavage for 90 d.
Rotarod Analysis
Groups of treated and nontreated littermates were placed on a
round bar that was rotating initially at 16 rpm. The rotation speed
was increased every minute from 16 to 36 rpm in steps of 4 rpm.
The holding time of animals on the rotating rod was measured,
and they were allowed to stay on the rod for a maximum of 270
s. Each animal was tested in two sessions of three trials each per
day for 3 consecutive days.
Curcumin Bioavailability Assay
Two different age groups of mice (2-wk-old and 3-mo-old Tr-J
mice) were treated with 100mg of curcumin per kg of bodyweight
by gastric lavage. At 0, 30, or 120 min after curcumin adminis-
tration, animals were euthanized with isoﬂurane. Blood was col-
lected by heart puncture and was mixed with EDTA (pH 8.0).
Brain, liver, and sciatic nerve tissues were removed and homog-
enized with 0.1 M KH2PO4 (pH 3.0) and then were extracted twice
with ethylacetate:isopropanol (9:1 v/v). The organic phase was
dried under argon and then was resolved with 50% acetonitrile
containing 0.1% triﬂuoroacetic acid (TFA). The samples were in-
jected into a C18 column, and the curcumin was eluted with an
acetonitrile gradient from 30% to 100%. Because of the low
amount of curcumin in the small volume of sciatic nerve, cur-
cumin was not detectable in sciatic nerves by a UV/visible (UV/
VIS) detector. We used ﬂuorescence detectors for curcumin de-
tection in sciatic nerves. For mass spectrometry, mass spectral
analysis was performed on a Finnigan LCQ DecaXP-plus quad-
rupole ion-trap mass spectrometer (ThermoFinnigan). The cur-
cumin standard (Sigma) and elution fractions from high-perfor-
mance liquid chromatography (HPLC) of mouse tissue extracts
were dissolved in 50% acetonitrile (v/v) containing 0.1% TFA.
The sample was loaded in an EconoTip (NewObjective), which
was mounted on the nanospray electrospray ionization tip adap-
tor. Samples were analyzed in positive ionization mode over the
range 150–1,000 m/z. The ion spray voltage was set at 2.0 kV,
capillary temperature was 250C, capillary voltage was 20 V, tube
lens offset was 5 V, ion gauge pressure was Torr, ac-51.2# 10
tivation Q-value was 0.25, normalized collision energy was 35%,
and the tandem mass spectrometry (MS/MS) isolation width was
1.0 m/z. The curcumin [MH] ion at 368.2 m/z was selected as
the parent ion for the MS/MS scan. The fragmentation pattern
of each elution fraction in the MS/MS analysis was manually
compared with that of the curcumin standard.
Electron Microscopy
Sciatic nerves were harvested from mice euthanized with isoﬂur-
ane. The nerves were immersion ﬁxed in 2.5% gluteraldehyde
and 0.5% paraformaldehyde in 0.1M phosphate buffer for at least
2 h and were postﬁxed in 1% osmium tetroxide before being
embedded in Spurrs resin. For light microscopy, 1-mm sections
were stained with paraphenylenediamine and were observed by
phase-contrast optics on a Zeiss Axioskop 2. For electron mi-
croscopy, thin sections were counterstained with lead citrate and
uranyl acetate. For statistical analysis, we performed a one-way
analysis of variance (ANOVA) on the normalized data. The F sta-
tistic for this ANOVA was , for an F statistic on 3 andFp 2,459.3
3,213 df.
Results
Curcumin’s Reversal of Induction of Apoptosis
Previous studies have shown that PMP22 is associatedwith
ER chaperones during normal folding and that such in-
teractions are more prolonged with PMP22 mutants
during quality control, causing retention in the ER of
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Figure 2. Increased cell death in HeLa cells after transfection with Tr-J and Tr mutations. A, Apoptosis induced in HeLa cell lines
after transient transfection (scale barp 25 mm). Cell lines transfected with wild-type (Wt) PMP22 (b) show a signiﬁcantly lower number
of positive cells. Data from TUNEL assays revealed the presence of more TUNEL-positive cells only after transfection with Tr-J (c) and
Tr (d) mutations. Negative control cells (a) transfected with empty plasmid are also shown. B, Western-blot analysis showing similar
PMP22 protein levels (arrow) for both wild-type and mutants in transiently transfected HeLa cell lines. Quantitative RT-PCR experiments
revealed equal amounts of mRNA in the experimental and control samples, which is consistent with the western blots (not shown). C,
Representative study of the ﬂow-cytometric analysis of apoptosis after transfection of cells with wild-type PMP22, Tr-J, and Tr. Signiﬁcant
differences were observed in the percentage of cells undergoing apoptosis when transfected with Tr-J and Tr, showing a higher toxic
effect of those mutations on cells compared with that of wild-type PMP22 (representative data are from one of four independent
experiments with comparable results). FS p ﬂow-sorted cells; PI p propidium iodide.
Schwann cells.24,25,30 Both overexpression of wild-type
PMP22 and mutant Tr-J protein form a complex with cal-
nexin, a Ca2-binding chaperone, that contributes to ER
retention.30 To independently verify these earlier ﬁndings
in our experimental paradigm, we transiently transfected
wild-type PMP22 cDNA and Tr-J and Tr mutations in HeLa
cells. HeLa cells transfected with wild-type PMP22 ex-
pressed the PMP22 protein on the plasma membrane, and
both Tr-J and Tr mutants were detectable within the cell
and were not incorporated into plasma membrane (ﬁg.
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1A). Accumulation of mutant PMP22 in the ER could be
potentially accounted for by its interaction with calnexin
and perhaps the triggering of the unfolded protein re-
sponse; however, markers of the unfolded protein re-
sponse are not signiﬁcantly changed in heterozygous Tr-
J sciatic nerves.30,31 Alternatively, aggregation of Tr-J and
Tr mutants in the ER and formation of a complex with
calnexin may instead compromise the ability of calnexin
to retain GD3 synthase (ST8), a key component for cer-
amide-induced apoptosis,32 thus sensitizing the cells to
apoptosis.
To determine whether the death of cells expressing
Tr-J and Tr mutants are apoptotic, we performed TUNEL
labeling on cells transfected with wild-type and PMP22
mutants. We quantiﬁed the number of positive cells by
counting all TUNEL-positive cells and DAPI-positive nu-
clei in 10 sections of the chamber slides. We found a large
number of positive cells among those transfected with Tr-
J and Tr compared with cells expressing wild-type PMP22
( and , respectively) (ﬁg. 2A). To ex-Pp .00014 Pp .0089
clude the possibility that the apoptosis may represent a
nonspeciﬁc consequence of protein overexpression, we
performed a western analysis. We found similar PMP22
protein levels for both wild type and mutants in tran-
siently transfected HeLa cell lines (ﬁg. 2B). We also doc-
umented equal amounts of PMP22 mRNA in the experi-
mental and control samples by quantitative RT-PCR
experiments, consistent with the western analysis (data
not shown).
As an independent experimental approach, we also used
a combined annexin V–propidium iodide assay to quan-
tify cell apoptosis of transiently transfectedHeLa cellswith
Tr-J and Tr mutations. Our analyses conﬁrmed that Tr-J
and Tr mutations induce apoptosis, with the annexin V–
positive cells reaching percentages of 25.9% and 32.5%,
respectively (ﬁg. 2C). Interestingly, cells transfected with
wild-type PMP22 contained a relatively higher percentage
of apoptotic cells (13.1%) than did the negative control
transfected with empty plasmid (4%) (ﬁg. 2C). This may
result from overexpression of wild-type PMP22 that can
accumulate to a level in ER that is toxic to cells.
We showed recently that ER-retained MPZ-truncating
mutants, associated with severe forms of peripheral neu-
ropathy, are released into the cytoplasm after curcumin
supplementation, apparently enabling more-efﬁcient pro-
tein processing. Such improved processing is accompanied
by reduced apoptosis.29 To assess whether curcumin treat-
ment is sufﬁcient to mitigate the toxic effect of PMP22-
mutant aggregation in cells, we measured cell apoptosis
after treatment with curcumin in HeLa cells transiently
transfected with PMP22 mutants for 24 h (ﬁg. 3). Notably,
we observed a decrease in apoptosis, possibly after more-
efﬁcient protein processing, by treating the cells with 40
mM of curcumin (ﬁgs. 1B and 3). The percentage of apo-
ptotic cells after treatment (12.3% and 15.9% for Tr-J and
Tr, respectively) is reduced from that observed without
curcumin treatment and is similar to that observed for the
wild-type PMP22 (ﬁg. 3).
Improved Motor Performances with Curcumin Treatment
The above studies document that curcumin can mitigate
the toxicity of neuropathy-causing PMP22 mutant pro-
teins in cell culture, as we demonstrated elsewhere for
disease-associatedMPZmutants.29 We then sought to eval-
uate the potential therapeutic use of oral curcumin sup-
plementation in vivo by use of the Tr-J mouse model. We
treated 20 newborn Tr-J mice (13 female and 7 male) with
daily doses of curcumin (50 and 100 mg per kg of body
weight) by force feeding orally for 90 d. We also admin-
istered the placebo (containing alimentum only) to 6 fe-
male and 5 male mice. Curcumin dosing was based on
previous studies and on what is apparently tolerated in
humans, calculated on the basis of dosage weight per body
weight.33 After treatment, we measured the motor perfor-
mances of each animal by the standard rotarod test. This
allowed us to compare the motor coordination and bal-
ance of the treated and untreated groups of mice.
In a series of 10 consecutive trials, the duration that the
animals remained on the stepwise-accelerating rotating
rod was measured and plotted (ﬁg. 4A). We observed a
signiﬁcant difference ( ) inmotor performance be-P ! .0001
tween treated (with 50 or 100 mg/kg curcumin) and un-
treated Tr-J mice (ﬁg. 4A). Tr-J mice were able to remain
on the rotarod for a shorter period of time (average 7 s)
than were wild-type and treated Tr-J mice (average 270 s
and 155 s, respectively). Treatment at the higher dose of
100 mg/kg showed a greater improvement in motor per-
formance (ﬁg. 4A); thus, we continued the higher dose.
Although the average walking time spent on the rod for
treated Tr-J mice was less than the time for the wild-type
mice, mice of both sexes treated with curcuminperformed
signiﬁcantly better than did the placebo and untreated Tr-
J mice ( ) (ﬁg. 4A). Curcumin treatment did notP ! .0001
affect the growth of the animals, as evidenced by serial
weight measurements, and had no apparent toxic effect
at the doses tested in our study, as revealed by comparison
of treated and untreated wild-type animals (data not
shown).
To determine whether this improvement in Tr-J motor
performance was a direct result of curcumin treatment,
we performed a second series of trials, using identical con-
ditions to the ﬁrst trial, except that curcumin supplemen-
tation was discontinued after 3 mo of treatment. As in the
ﬁrst trial, we conﬁrmed the initial improvement of motor
performance in the standard rotarod test after curcumin
treatment (ﬁg. 4B). We did not observe a signiﬁcant dif-
ference in motor performance of Tr-J mice within 1 mo
after discontinuation of treatment (trials 12–22; ﬁg. 4B);
however, 2 mo after treatment was ceased (trials 23–26),
Tr-J mice started to weaken signiﬁcantly compared with
those that were treated continuously ( ) (ﬁg. 4B).P ! .001
Our data indicate a dose-dependent signiﬁcant improve-
www.ajhg.org The American Journal of Human Genetics Volume 81 September 2007 443
Figure 3. Curcumin’s reversal of induction of apoptosis. Shown are results of apoptosis analysis of cells transiently transfected with
wild-type (Wt) PMP22, Tr-J, and Tr mutations after curcumin treatment. Note that the percentage of apoptotic cells after curcumin
treatment is signiﬁcantly different from that observed for no treatment (ﬁg. 2) (representative data are from one of four independent
experiments with comparable results). FS p ﬂow-sorted cells; PI p propidium iodide.
ment of motor coordination and muscle strength in Tr-J
mice treated with oral curcumin supplementation that is
reversed after curcumin withdrawal.
We also treated a limited number of adult Tr-J animals
(data not shown) but discontinued the treatment because
we observed no signiﬁcant improvement in phenotype.
We noted that a greater improvement in phenotype was
seen when newborn Tr-J mice were treated than when
treatment was initiated in adulthood.
Decreased in Vivo Cell Death of Schwann Cells
with Curcumin Treatment
Experiments in vivo have suggested a signiﬁcant increase
in apoptotic Schwann cells in sciatic nerves of 3-wk-old
Tr mice that continues to be prominent in adult mutant
mice, compared with wild-type mice.34 We measured the
frequency of Schwann cell apoptosis in sciatic nerves of
Tr-Jmice.We observed a considerable number of apoptotic
cells in Tr-J mice, whereas there was only minor or no
detectable cell death in the sciatic nerves from wild-type
animals (ﬁg. 5A). As observed in earlier studies ofTrmice,34
we also detected a signiﬁcant increase in Schwann cell
density in nerves from our Tr-J animals, despite the in-
creased rate of cell loss, possibly reﬂecting the unmasking
of axon-derived Schwann cell mitogens, such as glial
growth factor (or heregulin). To evaluate whether curcu-
min may have similar effects on Schwann cells as those
seen in cell culture assays (i.e., reducing the cytotoxicity
Figure 4. Improved neuromotor behavior in treated Tr-J mice. A, Rotarod test performed with 3-mo-old wild-type (Wt), Tr-J, curcumin-
treated Tr-J, and placebo-treated mice. In three series and 10 trials, the time that animals remained on a rod was measured and plotted.
The rotation speed was increased every minute, from 16 to 36 rpm, in steps of 4 rpm. The mean holding time of curcumin-treated Tr-
J mice ( ) was signiﬁcantly higher than that of placebo and Tr-J mice ( ). All animals were allowed to stay on the rod fornp 20 np 10
a maximum of 270 s. B, Curcumin treatment was discontinued for a group of Tr-J mice ( ) after 3 mo of treatment. The rotarodnp 5
test was performed similar to as described above, after curcumin treatment followed by discontinuation of treatment (marked on the
X-axis with an asterisk [*]). We did not observe signiﬁcant difference in the motor performance of Tr-J mice at 1 wk (trials 12–14), 2
wk (trials 15–18), and 1 mo (trials 19–22) after withdrawal of curcumin. Tr-J mice started to weaken signiﬁcantly at 2 mo after treatment
was ceased (trials 23–26) ( ). A double asterisk (**) denotes the group of mice ( ) that were originally treated withP ! .001 np 5
curcumin for 3 mo and then had the treatment discontinued.
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Figure 5. In vivo TUNEL staining of longitudinal sections of Tr-J and treated Tr-J sciatic nerves. A, Longitudinal sections of sciated
nerve of wild-type (a), Tr-J (b), curcumin-treated Tr-J (c), and placebo-treated Tr-J (d) mice. The scale bar is 40 mm for the inset and
100 mm for the lower-power resolution. Arrows indicate TUNEL-positive cells. B, Western-blot analysis showing similar PMP22 protein
levels for both wild-type (Wt) and Tr-J mice before and after curcumin treatment. C, Quantiﬁcation of apoptosis in the sciatic nerves
of wild-type, curcumin-treated, and placebo-treated Tr-J mutants. D, Quantitative analysis of cell density per mm2 in wild-type control,
Tr-J, placebo-treated Tr-J, and curcumin-treated Tr-J sciatic nerves. An asterisk (*) and a dagger (†) denote statistically signiﬁcant
differences from the wild-type and curcumin-treated Tr-J mice, respectively. Note that there is no statistically signiﬁcant difference
between the Tr-J mice and the Tr-J mice treated with placebo.
of mutant proteins and lowering the percentage of apo-
ptotic cells [ﬁg. 3]), we examined, in a blinded fashion,
the cell death of Schwann cells in sciatic nerves of cur-
cumin-treated Tr-J mice and compared it with that in pla-
cebo-treated Tr-J and wild-type control mice.
We observed signiﬁcantly reduced Schwann cell apo-
ptosis ( ) in curcumin-treated Tr-J mice comparedP ! .001
with in placebo-treated Tr-J animals (ﬁg. 5A and 5C). Al-
though there is no evidence that curcumin may increase
or decrease the expression of Pmp22, western analysis of
curcumin-treated and placebo-treated Tr-J mice show
equal amounts of PMP22 protein before and after treat-
ment (ﬁg. 5B). This suggests that curcumin treatment con-
ceivably relieves the toxic effect of mutant PMP22 in Tr-
J mice and inhibits Schwann cell apoptosis, the in vivo
correlate to our cell culture assay. Notably, this results in
improvement of the clinical and neuropathologic phe-
notype of the Tr-J mice.
To conﬁrm the presence of curcumin in adult treated
Tr-J mice, we measured the level of curcumin in different
tissues at 0, 0.5, and 2 h after oral administration. We
found a considerable amount of curcumin in liver (1,086.3
ng/ml in adult and 403 ng/ml in pup) within 0.5 h after
treatment, which declined after 2 h (table 1). However,
curcumin levels peaked at 2 h in blood (1,079.27 ng/ml),
brain (330.14 ng/ml), and sciatic nerves (453.8 ng/ml) (ta-
ble 1). In a standard control, curcumin was detected and
analyzed by HPLC with UV absorption at a range of 190–
800 nm and by ion-selected monitoring in mass spec-
trometry (ﬁg. 6A and 6B). Curcumin detected in all tissue
samples of treated mice had the same retention time as
the curcumin standard (ﬁg. 7). We were also able to mea-
sure the concentration of curcumin present in tissues after
30 min and up to 2 h after treatment (table 1).
A previous study35 found very low levels of curcumin
present in serum after oral administration, raising ques-
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Table 1. Curcumin Bioavailability Study in Mice
Sample
Tissue
Amount
Curcumin
(ng)
Curcumin
Concentration
(ng/ml)
Adult mouse:
Liver (0 h) .19 g UD UD
Liver (.5 h) .23 g 249.85 1,086.30
Liver (2 h) .21 g 98.59 469.50
Blood (0 h) .23 ml UD UD
Blood (.5 h) .40 ml 150.83 377.08
Blood (2 h) .35 ml 377.74 1079.27
Brain (0 h) .16 g UD UD
Brain (.5 h) .19 g UD UD
Brain (2 h) .15 g 49.52 330.14
Sciatic nerve (0 h)a .028 g UD UD
Sciatic nerve (.5 h)a .03 g UD UD
Sciatic nerve (2 h)a .034 g 15.43 453.82
2-wk-old pup:
Liver (0 h) .17 g UD UD
Liver (.5 h) .08 g 32.26 403.36
Liver (2 h) .13 g 32.51 250.07
Blood (0 h) .12 ml UD UD
Blood (.5 h) .15 ml UD UD
Blood (2 h) .1 ml 33.46 334.61
Brain (0 h) .34 g UD UD
Brain (.5 h) .26 g UD UD
Brain (2 h) .20 g 37.28 186.41
Sciatic nerve (0 h)b .018 g UD UD
Sciatic nerve (.5 h)b .024 g 15.20 633.33
Sciatic nerve (2 h)b .0225 g 15.18 674.67
NOTE.—UD p undetectable.
a Curcumin was not detectable in sciatic nerves by UV/VIS detector.
We used a pool of two adult mice samples, and curcumin was detected
by ﬂuorescence detectors.
b Curcumin was not detectable in sciatic nerves by UV/VIS detector.
We used a pool of three pup samples, and curcumin was detected by
ﬂuorescence detectors.
tions about the bioavailability of the compound to tissues
and target cells. We have also found that the levels of
curcumin in serum are very low, virtually undetectable by
use of our methods (data not shown). This result is not
surprising, because curcumin is a very hydrophobic com-
pound and would be expected to partition into cellular
membranes. Our analysis of whole blood and tissues con-
ﬁrms that this is the case and that orally administered
curcumin does indeed make its way into tissues through-
out the body, including the brain and peripheral nerves.
We used a ﬂuorescence detector to determine the amount
of curcumin in sciatic nerve, because of the low volume
of nerve tissue. The total amount of curcumin detected
was lower than in other tissues, despite its high concen-
tration in nerve (ﬁg. 6C). The concentration of curcumin
in sciatic nerve of treated Tr-J mice is apparently sufﬁcient
to reduce the cytotoxicity of mutant PMP22 in the mice
(ﬁg. 5C). Interestingly, curcumin concentrations in sciatic
nerves of treated 2-wk-old Tr-J pups were higher than
those in treated adult Tr-J mice (table 1). A combination
of higher curcumin bioavailability and more-active mye-
lination in Tr-J pups may account for the greater improve-
ment observed in the phenotype of newborn treated Tr-J
mice than Tr-J mice treated during adulthood.
We also compared the cell density in sciatic nerves of
curcumin-treated Tr-J mice with that in wild-type and pla-
cebo-treated Tr-J mice. Interestingly, we detected a de-
crease in Schwann cell density in sciatic nerves of treated
Tr-J mice (ﬁg. 5D), suggesting a possible reduction of cell
proliferation as a result of either more successful myeli-
nation or less demyelination of axons by Schwann cells
in the treated Tr-J animals. These data imply that pre-
mature apoptotic death of Schwann cells due to ER reten-
tion of mutant PMP22 may be a pathomechanism re-
sponsible for the inability of Tr-J mice to form normal
myelin and that treatment with curcumin reduces the cy-
totoxicity of mutant proteins by lowering the percentage
of apoptotic Schwann cells (ﬁg. 5C).
Improved Axonal Size and Decrease in Neuroﬁlament (NF)
Density with Curcumin Treatment
To understand better the basis for the clinical and neu-
ropathologic improvement in animals associatedwithoral
curcumin supplementation, we performed a morpholog-
ical analysis of sciatic nerves of curcumin-treated and pla-
cebo-treated Tr-J mice (ﬁg. 8A). We measured both the
axonal and ﬁber diameters of ∼2,000 myelinated axons
(table 2) from three curcumin-treated Tr-J mice, three pla-
cebo-treated Tr-J mice, and two wild-type mice. Placebo-
treated Tr-J mice showed histological hallmarks of CMT1,
as observed previously in Tr-J mice,17 whereas curcumin-
treated Tr-J mice had a higher average ﬁber and axonal
size (ﬁg. 8B and 8C and table 2). In addition, curcumin-
treated Tr-J mice had signiﬁcantly ( ) increased16Pp 10
myelin thickness (g ratio [SD] of ; )0.74 0.07 np 3
compared with that of placebo-treated Tr-J mice (g ratio
of ; ) (ﬁg. 8D and table 2). Thus, the com-0.81 0.07 np 3
bination of increased axonal caliber and myelin thickness
may explain the phenotypic improvement in curcumin-
treated Tr-J mice.
We also analyzed the NF densities by electron micros-
copy in cross-sections through axons of sciatic nerves from
placebo-treated Tr-J, curcumin-treated Tr-J, and wild-type
control mice (ﬁg. 9). NFs were spaced randomly through-
out cross-sections of all samples, which allowed an ac-
curate calculation of NF densities. We did not characterize
NF densities in nodal and paranodal regions because those
regions have increased NF densities compared with those
of normal axons.36 We selected axons with similar diam-
eters from each animal, and the observer was blinded to
genotype and treatment status. There were 195 32.75
NFs per mm2 in control (wild-type) mice, NFs265 37.75
per mm2 in curcumin-treated Tr-J mice, and 485 41.15
NFs per mm2 in placebo-treated Tr-J mice axons. This rep-
resents a signiﬁcant difference between curcumin-treated
and placebo-treated animals ( ). Such a decreaseP ! .0001
in NF density suggests increased spacing between NFs that
is correlated with higher NF phosphorylation and is di-
rectly modulated by axon–Schwann cell interactions dur-
ing myelination.37 This observation agrees well with our
earlier ﬁndings by light microscopy of increased axonal
Figure 6. HPLC and mass-spectrometry analyses of curcumin. A, Curcumin detected with UV/VIS (190–800 nm) or ﬂuorescence
(excitation at 430 nm; emission at 540 nm) detectors. B, Veriﬁcation of the peak corresponding to curcumin by mass spectrometry
(MS) analysis. C, HPLC analysis of sciatic nerves after curcumin treatment. Because of the low levels of curcumin in sciatic nerves,
curcumin was not detectable by UV/VIS; instead, ﬂuorescence detectors were used. The curcumin peak (arrow) in the sciatic nerves
had the same retention time as in the curcumin standard. No peak was observed at this position in samples from mice that did not
receive curcumin treatment.
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Figure 7. Curcumin bioavailability assayed by HPLC analysis in multiple tissues after curcumin treatment. Curcumin has a retention
time of 20 min in the standard (A). Curcumin was detected in liver (B), blood (C), and brain (D) of 2-wk-old pups after curcumin
treatment. We also detected curcumin in treated adult mice in a similar pattern.
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Figure 8. Histopathology and quantitative analyses of normal, Tr-J, and treated Tr-J sciatic nerves. A, Note the difference in morphology
and mean axonal diameter of myelinated ﬁbers in wild-type normal (a), Tr-J (b), curcumin-treated Tr-J (c), and placebo-treated Tr-J (d)
sciatic nerves from 3-mo-old mice. Scale barsp 10 mm. B, Distribution of ﬁber size (based on diameter) in Tr-J (red), curcumin-treated
Tr-J (white), and wild-type control (blue) mice. C, Distribution of axonal size in Tr-J (red), curcumin-treated Tr-J (white), and wild-type
control (blue) mice. D, Normalized plot of g ratios within each group, to account for the trends (nonlinear) between axon size and the
ratio observed in the wild-type mice.
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Table 2. Comparison of the Morphological Characteristics of Wild-Type, Tr-J,
and Treated Tr-J Sciatic Nerve
Characteristic Wild Type Tr-J Treated Tr-J
Tr-J with
Alimentum
Only
Mean axonal diameter of
myelinated ﬁbers (mm) 4.82  1.2 3.73  1.21 4.10  1.29 3.75  1.16
Mean ﬁber diameter (mm) 6.88  1.4 4.63  1.23 5.41  1.34 4.61  1.20
g ratio .69  .05 .80  .06 .74  .07 .81  .07
size andmoremyelinated axons in sciatic nerves of treated
Tr-J mice.
Discussion
We investigated the biological effect of curcumin in
Schwann cells of Tr-Jmice and evaluated its potential ther-
apeutic use for selected forms of inherited peripheral neu-
ropathies that result from protein misfolding or aggrega-
tion in the ER. We found that oral administration of
curcumin to newborn Tr-J mice signiﬁcantly improves, in
a dose-dependent manner, the motor coordination and
muscle strength of living mice by apparently relieving the
toxic effect of Tr-J and Tr aggregation–induced apoptosis
or generalized cell stress. The presence of curcumin in
blood and sciatic nerves (table 1) within 2 h after treat-
ment in both pups and adults demonstrates its bioavail-
ability for mitigating the toxic effect of PMP22 mutant
aggregation in Schwann cells, as observed in our cell cul-
ture assays. We also found that, even though the thickness
of the myelin sheath was reduced in curcumin-treated
mice in comparison with that in wild-type mice, it was
nevertheless sufﬁcient to improve the motor performance
of Tr-J mice as measured by the rotarod test.
We also analyzed the possibility that the pathological
improvements may be the result of curcumin’s action
through the NF-kB pathway. NF-kB inhibition is known to
reduce macrophages, and an increased number of mac-
rophages has been observed in sciatic nerves of animal
models for CMT1A,38 suggesting that macrophages may
play an active role in myelin degeneration. Given this
observation, we performed a macrophage-speciﬁc F4/80
stain on sciatic nerves of wild-type, untreatedTr-J,placebo
Tr-J, and curcumin-treated Tr-J mice and observed no sig-
niﬁcant change in macrophages between our tested
groups of mice (data not shown). In aggregate, these data
suggest that curcumin relieves the toxicity and/or cell
stress associated with the Tr-Jmutation and enables amore
efﬁcient protein-trafﬁcking process in the ER that can re-
sult in increased axonal size and myelination that is suf-
ﬁcient to improve the clinical phenotype of Tr-J mice.
Many diseases are linked to the accumulation of pro-
teins in the ER, suggesting that misfolding often occurs
in that cellular compartment.39 Protein misfolding can
contribute to disease through different mechanisms. Dis-
ease etiology may result when the efﬁciency of productive
folding and/or trafﬁcking is reduced to a threshold point
at which there is not enough properly trafﬁcked, func-
tional protein to maintain normal physiological function
(i.e., a loss-of-function diseasemechanism). An alternative
is a gain-of-function disease mechanism, in which the ab-
errant protein actively promotes pathogenesis due to
changes of normal protein function40 or formationof toxic
aggregates, such as amyloid.28
We evaluated the use of curcumin for treatment of se-
vere forms of CMT that are caused by mutant proteins
with a gain of function and with a more deleterious effect
because of being misprocessed in the cell.41 Our data doc-
ument the reduction in the percentage of apoptotic cells
for mutants in cell culture. In vivo studies conﬁrmed the
ﬁndings of our cell culture assays and showed reduced
apoptosis in biopsies of sciatic nerves from curcumin-
treated Tr-J mice. The point at which PMP22 in Tr-J exerts
its apparent cytotoxic effects has not been determined,
but putative “gain-of-function” effects of PMP22 with the
Tr-J mutation include sequestration of ER chaperones,
such as calnexin; the formation of aggregates (presumably
in the ER); or inhibition of post-ER (cytoplasmic) protein-
degradation pathways. However, histological analyses of
curcumin-treated Tr-J mice nerves (ﬁgs. 5 and 8) display
a morphologic phenotype that is less severe than that
which results from a gain-of-function Tr-J mutation. Cur-
cumin treatment could potentially lessen ER accumula-
tion and improve trafﬁcking of Schwann cell proteins in
general or PMP22 in particular, resulting in improvedmy-
elination of Schwann cells, a decrease in NF densities, and
an increased axonal caliber.
Our data could be important not only for patients with
inherited peripheral neuropathies but also for patients
with other diseases caused by aberrant proteins that pro-
mote disease etiology by the formation of toxic aggregates.
Curcumin treatment of animal models also provides a bet-
ter understanding of the pathological diseasemechanisms
caused by ER-retained mutants, such as the majority of
rhodopsin mutants that have been linked to phenotypes
of retinitis pigmentosa42 or mutant proteolipid proteins
that cause Pelizaeus-Merzbacher disease (PMD), aCNS dys-
myelinating disorder.43 A misfolded protein can accumu-
late to a level in which ER-associated degradation (ERAD)
gets overwhelmed, resulting in oversaturation of the com-
ponents of ERAD. For example, the myelin proteolipid
protein (PLP) is produced in vast quantities bymyelinating
oligodendrocytes.44 Abnormal amounts of disrupted pro-
teolipid proteins in the ER can overwhelm both ERAD and
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Figure 9. A, Electron micrographs of normal, Tr-J, and treated Tr-J sciatic nerves. In wild-type control mice (a), NFs are relatively
sparse (arrows), whereas, in Tr-J mice (b), the NFs are increased in number. In curcumin-treated Tr-J mice (c), NFs (arrows) become less
compact compared with those in untreated Tr-J mice (b). Scale bars p 0.2 mm. B, Calculation of the average number of NF per axonal
diameter in wild-type control, Tr-J, and curcumin-treated Tr-J mice. NFs are increased signiﬁcantly ( ) in number in Tr-J miceP ! .001
compared with in curcumin-treated Tr-J mice and wild-type mice.
normal export pathways, potentially provoking the un-
folded-protein response and major changes in cell phys-
iology that result in oligodendrocyte apoptosis in PMD
animal models.45
In such cases, rational drug design could be based on
different principles, such as interfering with chaperone
activity, enabling misfolded proteins to traverse out of the
ER, or potentially modulating protein folding.46 Analysis
of curcumin bioavailability (table 1) has also shown the
presence of curcumin in brain within 2 h after treatment
(with 100 mg of curcumin per kg of body weight) in both
pups and adults tested in our study, suggesting that it
might cross the blood-brain barrier and reach the brain
in treated mice. Thus, curcumin could be a promising new
therapeutic agent and may prove useful for disorders such
as PMD, since it appears to be stable and present in brain
with no apparent toxic effects. However, further investi-
gation to determine the direct effects of curcumin on PLP
mutants in cell culture is necessary. Curcumin can appar-
ently rescue misfolded proteins by potentially interfering
with the function of ER calcium-dependent chaperones.26
However, curcumin modulates a number of cellular mes-
senger pathways, including NF-kB and intracellular cal-
cium,26,47 that have been associated with the regulation of
myelination.
In summary, there are a number of cellular mechanisms
by which curcumin could have acted on Tr-J nerves. First,
curcumin protects Schwann cells from apoptosis that is
induced by the presence of the PMP22 mutant protein.
The ability of curcumin to increase axonal caliber and
myelin thickness, without tomaculae formation, is con-
sistent with the hypothesis that curcumin relieves ERAD
stress caused by abnormal processing of PMP22 and/or
other Schwann cell proteins that are required for myeli-
nation. Finally, it is formally possible that curcuminmight
modulate signal-transduction pathways that regulate my-
elin gene expression. Alternatively, curcumin may act di-
rectly on neurons by acting on signal-transduction path-
ways, to mimic the trophic effect of myelinating Schwann
cells on axonal caliber. Although these latter two hypoth-
eses may serve to explain the clinical effects of curcumin
on the Tr-J neuropathy, they do not explain the reduced
rate of apoptosis observed in curcumin-treated Tr-J sciatic
nerves.
In conclusion, we have shown that curcumin treatment
partially mitigates the clinical and neuropathologic phe-
notype of Tr-J mice by relieving the toxic effect of the
mutant PMP22, thereby inhibiting Schwann cell apoptosis
and increasing axonal caliber and myelin thickness. Fur-
thermore, this positive clinical response to curcumin oc-
curs in a dose-dependent manner and is reversed after
withdrawal of treatment. Notably, there were no side ef-
fects observed in treated mice at each of the doses tested
in our study. Further studies are recommended with other
mouse models, such as Tr, Tr-m1H, or Tr-m2H19, that rep-
resent more-severe human peripheral neuropathy, as well
as with Pmp22-overexpressing mice, to evaluate the po-
tential use of curcumin for therapy of more selected forms
of inherited peripheral neuropathies. Such studies will
likely provide further insights into common pathome-
chanisms and enable a better understanding of the path-
ophysiology of these disorders.
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